Evidence map›Paper›PMID 41720580›Full record

ArticleBMJ global health2026

Drug-resistant tuberculosis in war and complex emergencies: jeopardising progress towards TB elimination and antimicrobial resistance control - a scoping review and perspective.

Ignacio Monedero-Recuero, Xiaolin Wei, Fabienne Jouberton, Raquel Duarte, María Rodríguez-Ortega, Mary Rosary T Santiago, Adekola Oyedokun Adekunle, Paul Daru, Irina Felker, Francesca Conradie and 8 more

Abstract readScoping Review
In one paragraph

Article in BMJ global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Drug-resistant tuberculosis in conflict zones: a neglected global emergency.Journal of clinical tuberculosis and other mycobacterial diseases · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ignacio Monedero-RecueroDamien Foundation, Brussels, Belgium ignacio.monederorecuero@actiondamien.be.ORCID 0000-0002-2959-571X
Xiaolin WeiDalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Fabienne JoubertonMédecins Sans Frontières, Paris, France.
Raquel DuarteInstituto de Ciências Biomédicas Abel Salazar, ICBAS, Porto University, Porto, Portugal.
María Rodríguez-OrtegaFundación San Juan de Dios, Madrid, Spain.
Mary Rosary T SantiagoFamily Health International, Manila, Philippines.
Adekola Oyedokun AdekunleInstitute of Human Virology Nigeria, Abuja, Nigeria.
Paul DaruFHI 360 Asia Pacific Regional Office, Bangkok, Thailand.
Irina FelkerFSBI Novosibirsk Research Institute of Tuberculosis of the Ministry of Health of the Russian Federation, Novosibirsk, Russian Federation.
Francesca ConradieDepartment of Clinical Medicine, University of the Witwatersrand Johannesburg Faculty of Health Sciences, Johannesburg, South Africa.
Afshan K IsaniJohn Snow Research and Training Institute, Islamabad, Pakistan.
Chen-Yuan ChiangTB Department, The Union, Paris, France.
Mariama MahmoudNational Leprosy and Tuberculosis Control Programme, Ministry of Health, Freetown, Sierra Leone.
Hamdan Mustafa HamdanNational TB Program Sudan, Khartoum, Sudan.
Sangeeta SharmaNational Institute of Tuberculosis and Respiratory Diseases, New Delhi, India.
Alena SkrahinaRepublican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus.
Hoang Thi Thanh ThuyNational Lung Hospital, Hanoi, Viet Nam.
Sha WeiShanghai Pulmonary Hospital, Tongji University, School of Medcine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNearly 300 million people globally require humanitarian assistance, primarily due to conflicts and complex emergencies (CE). Modern conflicts are increasingly prolonged, deadly and frequent, severely disrupting health systems and hindering the provision of quality tuberculosis (TB) care. Managing drug-resistant TB (DR-TB) in these settings is particularly challenging. War and post-war conditions could potentially amplify resistance. However, evidence on DR-TB in CE-affected countries remains scarce.

methodsA scoping review, including grey literature and consultation with implementing agencies, was conducted to analyse published experiences worldwide in delivering DR-TB care in CE.

resultsThe review included 16 peer-reviewed articles and 11 reports. Countries affected by war exhibit multiple risk factors for amplifying TB resistance. DR-TB management in CE is ongoing, yet diagnostic access is limited, with notification rates below 20% of estimated cases. Treatment success rates among those diagnosed are comparable to global averages. Innovative approaches, such as molecular tests, shorter regimens and patient-centred approaches, have achieved higher success rates. Information on vulnerable populations, including internally displaced persons, prisoners and children, remains minimal. Only one country had reliable information on DR-TB in prisoners (Iraq), accounting for one-third of the national resistant cohort. Most CE countries rely on external funding for DR-TB programmes.

conclusionsLike in other infectious diseases, war significantly alters DR-TB dynamics in affected countries and bordering or refugee-hosting countries, threatening progress towards TB elimination and exacerbating the global antimicrobial resistance crisis. While innovations have improved the feasibility of DR-TB care in CE, access remains severely constrained. Identified risk factors, challenges and priorities underscore the need for expanded TB support and targeted research, particularly for vulnerable populations in CE scenarios.

Indexed as

Antitubercular AgentsDisease EradicationEmergenciesTuberculosis, Multidrug-ResistantWarfareHumansAntitubercular AgentsGlobal HealthMedical microbiologyTuberculosisViolence

Identifiers

PMID41720580
PMCPMC12927337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.